Immatics N.V. (IMTX) vs LB Pharmaceuticals Inc (LBRX)

Immatics N.V. and LB Pharmaceuticals Inc are both Biotechnology companies. Immatics N.V. and LB Pharmaceuticals Inc are of similar size ($1.3B and $1.2B). LB Pharmaceuticals Inc has the higher net margin (0.00% vs −489.4%) and the lower return on invested capital (−1,304.8% vs −84.8%). Across the 12 metrics below, LB Pharmaceuticals Inc leads on 7 and Immatics N.V. on 5.

Valuation

Metric IMTX LBRX Biotechnology median
P/E n/m n/m 7.88
P/S 23.25 n/m 11.47
P/B 2.46 3.39 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 17.76 n/m 10.73
Earnings yield (22.22%) (9.22%) (28.84%)
Free cash flow yield (21.01%) (7.36%) (23.03%)

Profitability

Metric IMTX LBRX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (536.26%) 0.00% 0.00%
Net margin (489.35%) 0.00% 0.00%
Free cash flow margin (488.01%) 0.00% 0.00%
Return on equity (48.53%) (72.07%) (57.72%)
Return on assets (39.83%) (47.38%) (49.22%)
Return on invested capital (84.83%) (1,304.79%) 0.00%

Growth

Metric IMTX LBRX Biotechnology median
Revenue growth (TTM) (64.99%) — 5.64%
EPS growth (last fiscal year) (1,313.33%) 98.22% —
Revenue growth, 5-year CAGR 11.81% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IMTX LBRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.54 15.08 4.73
Net debt to EBITDA 2.04 9.90 0.96

Dividend

Metric IMTX LBRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric IMTX LBRX Biotechnology median
Market cap 1.26b 1.22b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack